How is it different from daily growth hormone?

A CTP fusion extends its half-life so it is injected once weekly instead of daily, while acting on the same growth hormone receptor pathway.

Is somatrogon proven to work?

Yes, in children with GHD: a phase 3 trial showed once-weekly somatrogon was non-inferior to daily somatropin for height velocity.

Can somatrogon be used for anti-aging or bodybuilding?

No. It is only studied and approved for growth hormone deficiency; using growth hormone for anti-aging or performance is unproven and can be harmful.

What are the main safety concerns?

Injection-site reactions are common, and clinicians monitor for glucose intolerance, intracranial hypertension, hip (slipped capital femoral epiphysis) issues, and scoliosis; it is not for acute critical illness or active cancer.

EMA-approvedaka Ngenla

Somatrogon — Complete Research Guide (2026)

Last updated 2026-06-30

TL;DR

Somatrogon (also known as Ngenla) is a peptide catalogued under Growth Hormone (Long-acting GH analog). It is described as: GH receptor. Documented context: Growth hormone deficiency. Neutral reference entry; EU status: EU-approved prescription medicine.

What is Somatrogon?

Somatrogon (brand name Ngenla) is a long-acting recombinant human growth hormone in which the C-terminal peptide (CTP) of hCG is fused to the hGH sequence to extend its half-life, allowing once-weekly subcutaneous dosing.

It is an approved prescription medicine for children and adolescents with growth hormone deficiency (GHD) (FDA approval 2023; EMA approval 2022; earlier approvals in Canada, Australia, and Japan).

Evidence is human and of high quality: a pivotal phase 3 randomized non-inferiority trial versus daily somatropin plus supporting phase 2/3 and extension data.

How does Somatrogon work?

Somatrogon binds and activates the growth hormone receptor, stimulating hepatic and peripheral IGF-1 production that drives longitudinal bone growth and anabolic metabolism.

CTP fusion slows clearance and prolongs receptor exposure, so a single weekly injection sustains GH signaling that would otherwise require daily somatropin.

What does the research say about Somatrogon?

Once-weekly somatrogon achieved non-inferior 12-month annualized height velocity versus once-daily somatropin in treatment-naive children with GHD. ^[1]
Weekly dosing lowered overall treatment burden compared with daily injections in a randomized burden assessment. ^[3]
Non-inferiority to daily somatropin was reproduced in a separate phase 3 trial in Japanese children with pediatric GHD. ^[2]

Clinical research & studies

The references below are the primary sources cited throughout this guide. Each links directly to PubMed or the regulator. Where evidence is preclinical (animal or in-vitro), that is stated rather than implied.

[1] Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study — Deal CL et al., Journal of Clinical Endocrinology and Metabolism 2022. (Phase 3 randomized controlled (non-inferiority) trial)
[2] Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study — Horikawa R et al., Hormone Research in Paediatrics 2022. (Phase 3 randomized controlled trial)
[3] Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study — Maniatis AK et al., Journal of the Endocrine Society 2022. (Randomized crossover patient-reported outcome study)
[4] An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency — Zadik Z et al., Journal of Pediatric Endocrinology and Metabolism 2023. (Phase 2 open-label extension)
[5] Extension of the Phase 3 Trial of Somatrogon in Children with Growth Hormone Deficiency: 3 Years of Safety and Efficacy — Stawerska R et al., Hormone Research in Paediatrics 2026. (Phase 3 open-label extension)
[6] Comparing the efficacy and safety of weekly somatrogon with daily somatropin to treat children with growth hormone deficiency — Deal CL et al., Therapeutic Advances in Endocrinology and Metabolism 2024. (Narrative review)

Dosing context

This is not medical advice or a usage recommendation. Dosing figures are reported research context only, cited from the published literature.

For context only: somatrogon is given as a fixed once-weekly subcutaneous injection with the dose set and adjusted by a treating endocrinologist based on weight, growth response, and IGF-1.

This is background information, not dosing guidance; actual prescribing, titration, and monitoring must be handled by a qualified clinician.

Side effects & safety profile

Class growth-hormone safety applies: the most common issues are injection-site reactions, and prescribers monitor for glucose intolerance/new-onset diabetes, intracranial hypertension, slipped capital femoral epiphysis, and progression of scoliosis.

Growth hormone products are contraindicated in acute critical illness, active malignancy, and (for some GH products) certain syndromes; therapy requires endocrinologist supervision and periodic IGF-1 monitoring.

Somatrogon is an approved pediatric endocrine drug, not an anti-aging, bodybuilding, or performance agent; use outside GHD indications is not supported and is potentially harmful.

Stacking & combinations

Combining growth hormone products with unapproved peptides, anabolic agents, or other GH analogues is not evidence-based, is not part of any approved regimen, and can compound endocrine and metabolic risks.

Finding Somatrogon vendors

This is an independent, neutral directory — we sell nothing and route no purchases. Use it to read regulatory context and (where available) genuine, moderated vendor information for your country.

Choose your country

We never list placeholder vendors. Pick your country to see neutral regulatory context.

Browse the directory

User reviews

No reviews yet

Reviews appear here once submitted and moderated. An aggregate rating is shown only after at least 5 genuine reviews — we never fabricate ratings.

Frequently asked questions

It is approved as a once-weekly treatment for children and adolescents with growth hormone deficiency; it is a prescription pediatric endocrine drug.

References

[1] Efficacy and Safety of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Phase 3 Study — Deal CL et al., Journal of Clinical Endocrinology and Metabolism 2022. PMID: 35405011. View sourceStudy: Phase 3 randomized controlled (non-inferiority) trialOnce-weekly somatrogon was non-inferior to daily somatropin for 12-month height velocity in treatment-naive children with GHD.
[2] Efficacy and Safety of Once-Weekly Somatrogon Compared with Once-Daily Somatropin (Genotropin) in Japanese Children with Pediatric Growth Hormone Deficiency: Results from a Randomized Phase 3 Study — Horikawa R et al., Hormone Research in Paediatrics 2022. PMID: 35417909. View sourceStudy: Phase 3 randomized controlled trialWeekly somatrogon showed non-inferior height velocity and comparable safety to daily somatropin in Japanese children with GHD.
[3] Treatment Burden of Weekly Somatrogon vs Daily Somatropin in Children With Growth Hormone Deficiency: A Randomized Study — Maniatis AK et al., Journal of the Endocrine Society 2022. PMID: 36101713. View sourceStudy: Randomized crossover patient-reported outcome studyPatients and caregivers reported lower treatment burden with once-weekly somatrogon than with daily somatropin.
[4] An open-label extension of a phase 2 dose-finding study of once-weekly somatrogon vs. once-daily Genotropin in children with short stature due to growth hormone deficiency — Zadik Z et al., Journal of Pediatric Endocrinology and Metabolism 2023. PMID: 36732285. View sourceStudy: Phase 2 open-label extensionLong-term weekly somatrogon maintained growth with a safety profile consistent with daily GH.
[5] Extension of the Phase 3 Trial of Somatrogon in Children with Growth Hormone Deficiency: 3 Years of Safety and Efficacy — Stawerska R et al., Hormone Research in Paediatrics 2026. PMID: 42224388. View sourceStudy: Phase 3 open-label extensionSustained height gains and no new safety signals were observed over three years of weekly somatrogon.
[6] Comparing the efficacy and safety of weekly somatrogon with daily somatropin to treat children with growth hormone deficiency — Deal CL et al., Therapeutic Advances in Endocrinology and Metabolism 2024. PMID: 39526285. View sourceStudy: Narrative reviewReview concludes weekly somatrogon offers efficacy comparable to daily somatropin with reduced injection frequency.

This article is for educational and research purposes only. Peptides discussed here are not approved for human consumption by the FDA, EMA, or equivalent regulators outside of specific clinical contexts. Always consult a licensed medical professional before any therapeutic use.